These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3265988)

  • 1. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
    Zmilacher K; Battegay R; Gastpar M
    Neuropsychobiology; 1988; 20(1):28-35. PubMed ID: 3265988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unexpected effect of L-5 hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin.
    van Praag HM; Korf J; Lequin RM
    Psychopharmacol Commun; 1976; 2(5-6):369-78. PubMed ID: 1088302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
    Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
    No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
    [No Abstract]   [Full Text] [Related]  

  • 4. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness.
    Mendlewicz J; Youdim MB
    J Affect Disord; 1980 Jun; 2(2):137-46. PubMed ID: 6448885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 5-hydroxytryptophan on H-reflex recovery curves in normal subjects and patients with affective disorders.
    Metz JT; Holcomb HH; Meltzer HY
    Biol Psychiatry; 1988 Mar; 23(6):602-11. PubMed ID: 3128339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 9. Instability in the response to DST in major depressions during treatment with 5-hydroxytryptophan and carbidopa.
    Lopez-Ibor JJ; Saiz-Ruiz J; Perez de los Cobos JC
    Acta Psychiatr Belg; 1985; 85(3):450-8. PubMed ID: 3876688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
    Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
    No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of a decarboxylase inhibitor (Ro 4-4602) on 5-HTP induced muricide blockade in rats.
    Bocknik SE; Kulkarni AS
    Neuropharmacology; 1974 Apr; 13(4):279-81. PubMed ID: 4546783
    [No Abstract]   [Full Text] [Related]  

  • 12. [An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease].
    Pezzoli G; Tesei S; Cossutta E; Ferrante C; Zecchinelli A; Scarlato G
    Clin Ter; 1988 Apr; 125(2):115-20. PubMed ID: 2973932
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G; Gerdes U; Lehmann K
    Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
    [No Abstract]   [Full Text] [Related]  

  • 15. MPTP: clinical implications.
    Stern G
    J Neural Transm Suppl; 1986; 20():77-81. PubMed ID: 3091763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode.
    Jangid P; Malik P; Singh P; Sharma M; Gulia AK
    Asian J Psychiatr; 2013 Feb; 6(1):29-34. PubMed ID: 23380314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human sleep and 5-HTP. Effects of repeated high doses and of association with benserazide (RO.04.4602).
    Autret A; Minz M; Bussel B; Cathala HP; Castaigne P
    Electroencephalogr Clin Neurophysiol; 1976 Oct; 41(4):408-13. PubMed ID: 60227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time and dose influences on the behavioral effects of L-DOPA and 5-hydroxytryptophan after inhibition of extracerebral decarboxylase.
    Gronan RJ
    Pharmacol Biochem Behav; 1975; 3(2):161-6. PubMed ID: 1079949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study.
    Nardini M; De Stefano R; Iannuccelli M; Borghesi R; Battistini N
    Int J Clin Pharmacol Res; 1983; 3(4):239-50. PubMed ID: 6381336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.